{"Clinical Trial ID": "NCT00191815", "Intervention": ["INTERVENTION 1:", "- Gemcitabine + Cisplatin", "- Gemcitabine dose (30 min intravenous infusion) of 1000 mg/m2 on day 1 and day 8 (21-day cycle).", "\u00b7 Cisplatin dose (30-120 min intravenous infusion) of 35 mg/m2 on day 1 and day 8 (21-day cycle)."], "Eligibility": ["Incorporation criteria:", "You're a woman between the ages of 18 and 75.", "You have been diagnosed with metastatic breast cancer.", "You have the desire and opportunity to consult your doctor at the medical site, both during the completion of the active treatment program, and within 24 months of the medical follow-up.", "You must sign this informed consent form.", "- Exclusion criteria:", "You are pregnant or breast-feeding.", "Your laboratory parameters are outside the limits, accepted by the requirements of this clinical study.", "You have been diagnosed with concomitant or acute serious infectious disease.", "You used experimental drugs in the last month."], "Results": ["Performance measures:", "Response of objective tumours", "The best response recorded from the start of treatment to the progression or recurrence of the disease using World Health Organization (WHO) criteria that define when participants improve (\"respond\"), remain the same (\"stable\") or worsen (\"progress\") during treatment.", "Time frame: baseline period to measure progressive disease (eight 21-day treatment cycles and follow-up period were 24 months from the date of last administration of the drug. Data collected every 4 months.)", "Results 1:", "Title of arm/group: Gemcitabine + Cisplatin", "Description of the arm/group: Gemcitabine (30 min intravenous infusion) 1000 mg/m2 dose on day 1 and day 8 (21-day cycle).", "\u00b7 Cisplatin dose (30-120 min intravenous infusion) of 35 mg/m2 on day 1 and day 8 (21-day cycle).", "Total number of participants analysed: 54", "Type of measurement: Number", "Unit of measure: Participants Complete response: 7", "Partial reply: 19", "Stable disease: 19", "Progressive diseases: 5", "Non-evaluable: 4"], "Adverse Events": ["Undesirable Events 1:", "Total: 6", "Atrial fibrillation 1/67 (1.49 %)", "Ventricular fibrillation 1/67 (1.49 %)", "gastrointestinal perforation value 1/67 (1.49 %)", "- Periproctitis 1/67 (1.49%)", "General deterioration of physical health 1/67 (1.49 per cent)", "Escherichia sepsis 1/67 (1.49 %)", "Pneumonia 1/67 (1.49%)", "- Tumor pain 1/67 (1.49%)", "Acute renal impairment 1/67 (1.49%)", "- Pleurisy 1/67 (1.49%)"]}